Different Effects of Atorvastatin and Pravastatin on Hemoglobin A1c in Hyperlipidemia Patients with Initially Normal Hemoglobin A1c
|
Accession number;07A0026932
|
| Title;Different Effects of Atorvastatin and Pravastatin on Hemoglobin A1c in Hyperlipidemia Patients with Initially Normal Hemoglobin A1c |
| Author;
MURAKAMI TAKASHI
(Sakakibara Hospital, Okayama)
HINA KAZUYOSHI
(Sakakibara Hospital, Okayama)
SOGOU TAIJI
(Takamatsu Red Cross Hospital, Takamatsu)
UEEDA MASAYUKI
(Mitoyo General Hospital, Kanonji)
KOMATSUBARA ISSEI
(Tsuyama General Hospital, Tsuyama)
TOMINAGA YOUKOU
(Yashima General Hospital, Takamatsu)
KUSACHI SHOZO
(Okayama Univ. Graduate School Of Health Sci., Okayama, Jpn)
|
Journal Title;Ther Res
|
Journal Code:Y0681A
|
ISSN:0289-8020
|
|
VOL.27;NO.11;PAGE.2105-2111(2006)
|
| Figure&Table&Reference;FIG.1, TBL.2, REF.25 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Several experimental and clinical studies have shown that different statins may affect glucose metabolism differently. Here we compared the effects on hemoglobin A1c (HbA1c) between atorvastatin and pravastatin in patients with hyperlipidemia without abnormal glucose tolerance. A prospective randomized study was performed in patients with hyperlipidemia without diabetes (HbA1c.LEQ.5.8%). HbA1c and serum lipid levels were determined before and 3-6 months after the start of either atorvastatin (5-10 mg/day) or pravastatin (10-20 mg/day) administration. Twenty-nine eligible patients were randomly assigned to two groups and administered atorvastatin (n=11) or pravastatin (n=18). There were no significant differences in HbA1c in the two groups before statin therapy. The atorvastatin-group patients showed a significant increase in HbA1c from 5.35.+-.0.30% to 5.57.+-.0.31% (p<0.05) 3-6 months after the administration. In 9 of 11 patients in this group (82%), HbA1c was increased by 0.3%. In contrast, HbA1c was not increased in the pravastatin group (5.21.+-.0.32 vs 5.24.+-.0.39%). Changes in HbA1c compared to baseline tended to be higher in the atorvastatin group (0.23.+-.0.24%) than in the pravastatin group (0.03.+-.0.24%, 0.05<p<0.10). Changes in HbA1c were not correlated with a reduction of serum lipids. In conclusion, the present study provide clinically helpful information regarding the treatment of hyperlipidemia patients with normal HbA1c. (author abst.) |
|
|
|
Related Articles;
|
|
